Leerink Partners analyst, Danielle Attafly, reiterated her Outperform rating on of Edwards Lifesciences (NYSE: EW) understanding that shares are likely ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE